Kestra Advisory Services LLC Has $4.70 Million Stock Holdings in Kenvue Inc. $KVUE

Key Points

• Kestra Advisory Services LLC reduced its holdings in Kenvue Inc. by 7.5%, now owning 196,104 shares valued at approximately $4.7 million.
• Kenvue recently declared an increased quarterly dividend of $0.2075 per share, raising its annualized dividend yield to 4.0%.
• Analysts have downgraded Kenvue’s price targets, with UBS reducing it from $25 to $23 and Zacks Research assigning a “strong sell” rating.

Kestra Advisory Services LLC lessened its position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 7.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 196,104 shares of the company's stock after selling 15,854 shares during the quarter. Kestra Advisory Services LLC's holdings in Kenvue were worth $4,703,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Pittenger & Anderson Inc. acquired a new position in shares of Kenvue during the first quarter valued at $30,000. TruNorth Capital Management LLC acquired a new position in shares of Kenvue during the first quarter valued at $36,000. Clal Insurance Enterprises Holdings Ltd lifted its stake in shares of Kenvue by 378.5% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company's stock valued at $39,000 after acquiring an additional 1,287 shares during the period. Bank Julius Baer & Co. Ltd Zurich lifted its stake in shares of Kenvue by 120.6% during the first quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,699 shares of the company's stock valued at $41,000 after acquiring an additional 929 shares during the period. Finally, Clarity Asset Management Inc. acquired a new position in shares of Kenvue during the fourth quarter valued at $45,000. Institutional investors and hedge funds own 97.64% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on KVUE. Royal Bank Of Canada cut their price target on Kenvue from $24.00 to $22.00 and set a "sector perform" rating on the stock in a research note on Friday, August 8th. Canaccord Genuity Group dropped their price objective on Kenvue from $29.00 to $26.00 and set a "buy" rating for the company in a report on Friday, August 8th. JPMorgan Chase & Co. dropped their price objective on Kenvue from $27.00 to $26.00 and set an "overweight" rating for the company in a report on Friday, July 25th. Barclays dropped their price objective on Kenvue from $23.00 to $22.00 and set an "equal weight" rating for the company in a report on Tuesday, July 15th. Finally, Bank of America dropped their price objective on Kenvue from $27.00 to $25.00 and set a "buy" rating for the company in a report on Tuesday, July 15th. Five equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $24.38.

Kenvue Stock Up 0.9%

Shares of NYSE KVUE traded up $0.18 during mid-day trading on Monday, reaching $20.72. 10,307,391 shares of the company's stock were exchanged, compared to its average volume of 17,119,262. The firm has a market capitalization of $39.76 billion, a price-to-earnings ratio of 27.99, a PEG ratio of 2.97 and a beta of 0.83. The company has a current ratio of 0.98, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. The business has a fifty day simple moving average of $21.46 and a 200 day simple moving average of $22.45. Kenvue Inc. has a twelve month low of $19.75 and a twelve month high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.29 EPS for the quarter, topping analysts' consensus estimates of $0.28 by $0.01. The company had revenue of $3.84 billion for the quarter, compared to analyst estimates of $3.94 billion. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.Kenvue's revenue was down 4.0% compared to the same quarter last year. During the same quarter last year, the firm posted $0.32 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, equities analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, August 27th. Stockholders of record on Wednesday, August 13th were given a dividend of $0.2075 per share. This is an increase from Kenvue's previous quarterly dividend of $0.21. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.0%. The ex-dividend date of this dividend was Wednesday, August 13th. Kenvue's payout ratio is 112.16%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.